Focus: Phantom Neuro develops robotic and neuromuscular interface technologies for upper limb prosthesis control, targeting amputees with innovative EMG-based instrumentation. The company operates as a pre-revenue biotech focused on musculoskeletal rehabilitation devices.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
Stable — net +1 jobs in 30d
6 added, 5 removed. Backfill posture.
Phantom Neuro is a high-risk, high-upside early-stage medical device startup best suited for engineers and product developers seeking deep technical ownership and equity upside, but unsuitable for those prioritizing financial stability or near-term product catalysts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Phantom Neuro
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Phantom Neuro's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles